Prof. David Chu is a distinguished research professor, emeritus, in the Department of Pharmaceutical and Biomedical Sciences at the University of Georgia. He established an internationally known academic drug discovery program for antiviral research. He has been serving as the director of the Drug Discovery Group at UGA since 1989. He discovered more than seven clinical candidates for HIV, cancer, and HBV; his anti-hepatitis B virus (HBV) agent, clevudine, marketed under the trade name Levovir, is being used for the treatment of chronic hepatitis B (CHB) infections in several countries in Asia. Most recently, his research group discovered FMCA for drug-resistant HBV, as well as L-BHDU for the treatment of shingles. Currently, his research group is focusing on the drug discovery project for SARS-COV-2, VZV, and HSA 1 and 2 infections. He is the recipient of prestigious international awards in antiviral drug discovery fields, including the John A. Montgomery Award (International RoundTable Society) and the Antonin Holy Award (Society of International Antiviral Research). He is an elected fellow of the National Academy of Inventors and the American Association of Advancement of Science. He is a recipient of the NIH Merit Award and Inventor of the Year Award of UGA. He has published over 300 peer-reviewed research papers and received 60 US patents. Whenever viruses threatened human health, his group has been at the forefront of the discovery of antiviral agents.